Timothy J Rink

Biography

Dr. Timothy J. Rink, also known as Tim, M.D., Sc.D, serves as Scientific Advisor at Amylin Pharmaceuticals Inc. and Aurora Biosciences Corp. Dr. Rink serves as an Advisor of Avelas BioSciences, Inc. He served as the Chairman, Chief Executive Officer and President of Aurora Biosciences Corp., from February 1996 to 1999. He served as the President and Chief Technical Officer of Amylin Pharmaceuticals Inc. from 1990 to 1995. He served from 1990 to 1999 in San Diego, California, building and growing biotechnology companies. From 1984 to 1989, He served as Vice President of Research of Smithkline Beecham in the UK. He serves as the Chairman of Scientific Advisory Board of Amylin Pharmaceuticals Inc. Dr. Rink has been a Member of Therapeutic Advisory Board at aTyr Pharma Inc. since March 1, 2011. He has been Lead Director of Kymab Limited since April 1, 2016. Dr. Rink has been a Director of Graffinity Pharmaceuticals GmbH since September 2001 and Sunovion Pharmaceuticals Inc. since October 12, 2005. Dr. Rink serves as a Director of Stevenage Bioscience Catalyst and Solex Limited. He served as a Director at Adnexus Therapeutics Inc. since August 21, 2007 an also served as Director for Kymab Limited. Dr. Rink served as a Member of Scientific Advisory Board of Santhera Pharmaceutical Holding AG. He served as a Non Executive Director of Akubio Limited. He served as Director of Santhera Pharmaceuticals Holding AG since 2004 until May 2013. He served as the Chairman of the Board of Solexa Inc. Dr. Rink served as a Director of Sepracor, Inc. since October 12, 2005. He served as a Director at Alanex, Ciphergen, Gryphon Sciences, Astex Therapeutics Limited and NPS Pharmaceuticals. He served as Non Executive Director of BioVex, Inc. since 2000. He served as a Director of CoCensys, Inc. since August 1990. He served as Independent Non Executive Director of Lorantis Limited. He served on the Scientific Advisory Board of Serono AG. Previously, he was chairman of the Wellcome Trust Technology Transfer Strategy Panel. Dr. Rink has been involved in the development of numerous therapeutics, including Requip, Protonix, Symlin, Byetta, Sensipar and Catena. He was an Associate Professor/a Lecturer in Physiology at University of Cambridge, from 1976 to 1984. Dr. Rink has MA, MD and ScD degrees from the University of Cambridge.  

Research Interest

 Dr. Timothy has research interest in Pharma, Bioscience, Biotechnology and Business Management.